Gene Editing Breakthrough: In Vivo CRISPR Therapy for HAE Completes Phase 3
A landmark Phase 3 study for an in vivo CRISPR therapy targeting hereditary angioedema has successfully concluded, offering new hope for this debilitating genetic condition.
A landmark Phase 3 study for an in vivo CRISPR therapy targeting hereditary angioedema has successfully concluded, offering new hope for this debilitating genetic condition.